Business Description
ACADIA Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US0042251084
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 7.67 | |||||
Equity-to-Asset | 0.58 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.84 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.08 | |||||
Beneish M-Score | -1.7 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.4 | |||||
3-Year EBITDA Growth Rate | 38.8 | |||||
3-Year EPS without NRI Growth Rate | 40.9 | |||||
3-Year FCF Growth Rate | 46.1 | |||||
3-Year Book Growth Rate | -12.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 19.62 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26 | |||||
9-Day RSI | 28.34 | |||||
14-Day RSI | 28.73 | |||||
6-1 Month Momentum % | -21.5 | |||||
12-1 Month Momentum % | -6.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.42 | |||||
Quick Ratio | 2.28 | |||||
Cash Ratio | 1.73 | |||||
Days Inventory | 137.65 | |||||
Days Sales Outstanding | 40.3 | |||||
Days Payable | 138.21 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1 | |||||
Shareholder Yield % | -0.73 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.27 | |||||
Operating Margin % | -10.1 | |||||
Net Margin % | -8.44 | |||||
FCF Margin % | 2.06 | |||||
ROE % | -15.6 | |||||
ROA % | -9.38 | |||||
ROIC % | -52.07 | |||||
ROC (Joel Greenblatt) % | -126.07 | |||||
ROCE % | -16.19 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 25.77 | |||||
PS Ratio | 3.84 | |||||
PB Ratio | 6.48 | |||||
Price-to-Tangible-Book | 7.64 | |||||
Price-to-Free-Cash-Flow | 173.47 | |||||
Price-to-Operating-Cash-Flow | 173.47 | |||||
EV-to-EBIT | -32.97 | |||||
EV-to-Forward-EBIT | 15.97 | |||||
EV-to-EBITDA | -35.67 | |||||
EV-to-Forward-EBITDA | 23.71 | |||||
EV-to-Revenue | 3.33 | |||||
EV-to-Forward-Revenue | 2.5 | |||||
EV-to-FCF | 144.86 | |||||
Price-to-Net-Current-Asset-Value | 9.34 | |||||
Price-to-Net-Cash | 22.97 | |||||
Earnings Yield (Greenblatt) % | -3.03 | |||||
FCF Yield % | 0.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
ACADIA Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 673.383 | ||
EPS (TTM) (€) | -0.361 | ||
Beta | 0.61 | ||
Volatility % | 62.06 | ||
14-Day RSI | 28.73 | ||
14-Day ATR (€) | 0.263324 | ||
20-Day SMA (€) | 16.34075 | ||
12-1 Month Momentum % | -6.67 | ||
52-Week Range (€) | 15.7 - 29.4 | ||
Shares Outstanding (Mil) | 164.77 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ACADIA Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ACADIA Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ACADIA Pharmaceuticals Inc Frequently Asked Questions
What is ACADIA Pharmaceuticals Inc(FRA:DR6)'s stock price today?
When is next earnings date of ACADIA Pharmaceuticals Inc(FRA:DR6)?
Does ACADIA Pharmaceuticals Inc(FRA:DR6) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |